This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
500
Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
U.S. Army Medical Research Institute of Infectious Diseases
Fort Deterick, Maryland, United States
Number of participants with a 80% plaque-reduction neutralization titer (PRNT80)
Time frame: 21-35 days, 42-56 days, 12-15 months
Number of adverse events.
Time frame: 7 years
Number of confirmed cases of VEE disease among vaccinated subjects who achieved a PRNT 80 ≥ 1:20.
Time frame: 7 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.